Today is World Hepatitis Day!
I have recently learned a lot about viral hepatitis and I’m just starting to understand how dynamic and complex a disease (multiple diseases, really) it is. In the United States, Hepatitis B (HBV) and Hepatitis C (HCV) are two distinct diseases, far more prevalent than can even be accurately counted, with intersecting social histories. Abroad, HBV, HCV and Hepatitis A (HAV) have reached epidemic proportions in several regions. (To be clear HAV is present in the U.S., but has a relatively low incidence rate.)
While each hepatitis has its own specific disease profile, the populations affected by hepatitis are having distinctive experiences with the virus too. Still in the U.S…. For HBV we have a vaccine and (theoretically) the opportunity to eradicate this strand – HBV is primarily being spread through sexual contact (so for example there are higher rates in the “men who sleep with men” (MSM) population). HCV on the other hand is both acute and chronic, and currently there is no treatment which can “cure” chronic hepatitis C (no vaccine). The population most affected by chronic HCV are baby boomers, many of whom are completely unaware of their status until they develop cirrhosis of the liver and liver cancer (it is thought that many of these individuals contracted hepatitis C during the 60s and 70s). New HCV infections are highly prevalent among injection drug users (IDUs) – a fringe population very hard to understand, reach out to, and treat.
There can often be HIV/hepatitis co-infection, of both HBV and HCV, which can complicate treatment. Like with HIV in the 80s and 90s, hepatitis comes with stigmas, a lack of understanding from both health care professionals and patients, and a series of cultural factors which makes it an unknown.
Asian Americans, African Americans, those incarcerated, the undocumented, immigrants from countries such as Egypt and China, pregnant women, baby boomers, and IDUs all have specific needs and circumstances (goldmine for medical anthropologists?!). With infection rates far greater than those of HIV(in the U.S.) and research funding about a 10th of what HIV research gets, its seems about time we start paying some attention to hepatitis.

